Literature DB >> 9562103

Homonymous hemianopsia as the initial manifestation of multiple sclerosis.

K Gündüz1, K Cansu, S Bulduklar, I Saatçi.   

Abstract

A 28-year-old male patient in good health with no previous neurologic or ophthalmoscopic abnormalities developed right homonymous hemianopsia. Magnetic resonance (MR) imaging demonstrated bilateral high-signal suprageniculate lesions. The lesion located in the left parieto-occipital area was compatible with the field defect observed. Oligoclonal bands were present in the cerebrospinal fluid. Testing of visual-evoked potentials revealed increased latencies in both eyes. The patient was given 1 g/day intravenous methylprednisolone for 3 days. The visual fields, as determined by automated static perimetry, recovered completely in 2 weeks. Follow-up MR imaging at 1 month showed no change compared to baseline. Seven months after the initial attack he suffered right internuclear ophthalmoplegia, which resolved spontaneously within 1 week. Based on the clinical and radiologic findings, the final diagnosis was made as clinically definite multiple sclerosis (MS). This patient represents a rare case of MS presenting first with homonymous hemianopsia.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9562103     DOI: 10.1159/000027283

Source DB:  PubMed          Journal:  Ophthalmologica        ISSN: 0030-3755            Impact factor:   3.250


  2 in total

1.  In vivo demonstration of homonymous hemimacular loss of retinal ganglion cells due to a thalamic lesion using optical coherence tomography.

Authors:  Jiwon Oh; Elias S Sotirchos; Shiv Saidha; Mohamed Ibrahim; Yasir Sepah; Quan Dong Nguyen; Peter A Calabresi
Journal:  JAMA Neurol       Date:  2013-03-01       Impact factor: 18.302

2.  Retinal asymmetry in multiple sclerosis.

Authors:  Axel Petzold; Sharon Y L Chua; Anthony P Khawaja; Pearse A Keane; Peng T Khaw; Charles Reisman; Baljean Dhillon; Nicholas G Strouthidis; Paul J Foster; Praveen J Patel
Journal:  Brain       Date:  2021-02-12       Impact factor: 13.501

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.